Drugs / spCART-269
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04500431 | Jul 2018 → Jul 2022 | plasma cell myeloma | Shanghai Tongji Hospital, Tongji University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | spCART-269 | “The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of spCART-269 in treatment of relapsed or...” NCT04500431 ↗ |
| Modality | Cell therapy | “Targeting CD269 chimeric antigen receptor engineered T cells” NCT04500431 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT04500431 ↗ |